Teladoc Health, Inc. TDOC incurred a third-quarter 2024 adjusted loss of 19 cents per share, narrower than the Zacks Consensus Estimate of a loss of 29 cents and the year-ago quarter’s loss of 35 cents.
Operating revenues amounted to $610.5 million, which declined 3% year over year. The top line, however, beat the consensus mark by 1.6%.
Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.
The better-than-expected quarterly results were supported by growing International revenues, strength in the Integrated Care segment and declining expenses. However, a decline in access fees and BetterHelp’s revenues acted as a partial offset.
Teladoc Health, Inc. Price, Consensus and EPS Surprise
Teladoc Health, Inc. price-consensus-eps-surprise-chart | Teladoc Health, Inc. Quote
Quarterly Operational Update of TDOC
Revenues from access fees (which accounted for 86.7% of total quarterly revenues) declined 5% year over year to $555.3 million in the quarter under review. But the metric beat the Zacks Consensus Estimate by 2.1%.
Other revenues of $85.2 million increased 9% year over year and beat the Zacks Consensus Estimate by 3%.
On a geographical basis, Teladoc Health generated $536.2 million in revenues from the United States, down 6% year over year in the third quarter. The metric beat the consensus mark by 1%. International revenues rose 15% year over year to $104.3 million and outpaced the consensus mark by 12.8%.
Adjusted EBITDA fell 6% year over year to $83.3 million. The adjusted gross margin of 71.9% was up from 71.8% a year ago.
Total expenses decreased 5.5% year over year to $684.9 million in the quarter, lower than our estimate of $688 million. The year-over-year decline resulted from lower costs of revenues, advertising and marketing, sales, technology and development costs.
TDOC’s Segmental Update
The Integrated Care segment reported revenues of $383.7 million, which improved 2% year over year in the third quarter and surpassed the Zacks Consensus Estimate of $376.4 million and our estimate of $371.2 million. Adjusted EBITDA rose 8% year over year to $68 million, higher than the consensus mark of $57.4 million. Adjusted EBITDA margin of 17.7% improved from 16.8% a year ago.
The BetterHelp segment’s revenues declined 10% year over year to $256.8 million but beat the Zacks Consensus Estimate of $251.3 million and our estimate of $252.2 million. Adjusted EBITDA of $15.2 million fell 41% year over year and missed the consensus mark of $20.82 million. Adjusted EBITDA margin deteriorated to 5.9% in the quarter under review from 9.1% a year ago.
Visits & Memberships of TDOC
Total visits of Teladoc Health were 4.1 million, which slipped 7% year over year but came above the Zacks Consensus Estimate and our estimate of 4.03 million.
U.S. Integrated Care Members totaled 93.9 million as of Sept. 30, 2024, which improved 4% year over year. The metric beat the consensus mark by 1.1%.
Financial Update (as of Sept. 30, 2024)
Teladoc Health exited the third quarter with cash and cash equivalents of $1.24 billion, which slid from the $1.12 billion figure in 2023-end. Total assets of $3.53 billion fell from the 2023-end level of $4.39 billion.
Debt amounted to $990.6 million, which declined from the $1.54 billion figure as of Dec. 31, 2023. Total stockholders’ equity of $1.51 billion declined from the 2023-end level of $2.33 billion.
Operating cash flow amounted to $110.2 million in the third quarter of 2024, which increased 4.4% year over year. Free cash flows were $79 million in the quarter under review, up from $68 million a year ago. Capex decreased 17.3% year over year to $31.15 million.
Outlook
Fourth-Quarter View
Revenues in the Integrated Care segment are forecasted to witness 0-2.5% year-over-year growth, while the unit’s adjusted EBITDA margin is anticipated to remain within 12.25-13.75%. U.S. Integrated Care Members are expected to be between 93.5 and 94.5 million.
2024 View
Revenues in the Integrated Care segment are expected to witness low to mid-single-digit growth on a year-over-year basis.
U.S. Integrated Care Members are expected to remain within 93.5-94.5 million.
Adjusted EBITDA margin in the Integrated Care segment is estimated to be within 14.9%-15.3% in 2024.
Zacks Rank & Key Picks
Teladoc Health currently has a Zacks Rank #3 (Hold).
Some better-ranked and promising stocks in the broader Medical sector are Tenet Healthcare Corporation THC, CareDx, Inc CDNA and Encompass Health Corporation EHC. While Tenet Healthcare currently sports a Zacks Rank #1 (Strong Buy), CareDx and Encompass Health carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Tenet Healthcare’s 2024 bottom line suggests 63.2% year-over-year growth. THC has witnessed four upward estimate revisions over the past 30 days against no movement in the opposite direction. It beat earnings estimates in all the last four quarters, with an average surprise of 59.9%.
The Zacks Consensus Estimate for CareDx’s current-year earnings indicates a 142.2% year-over-year improvement. CDNA beat earnings estimates in each of the past four quarters, with an average surprise of 135.2%. The consensus mark for revenues suggests 16.8% growth from the year-ago period.
The Zacks Consensus Estimate for Encompass Health’s 2024 full-year earnings implies a 17.3% increase from the year-ago reported figure. EHC beat earnings estimates in each of the last four quarters, with an average surprise of 13.6%. The consensus mark for its current-year revenues is pegged at $5.34 billion, which indicates an 11.2% year-over-year increase.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpTenet Healthcare Corporation (THC) : Free Stock Analysis Report
Teladoc Health, Inc. (TDOC) : Free Stock Analysis Report
CareDx, Inc. (CDNA) : Free Stock Analysis Report
Encompass Health Corporation (EHC) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
